Shining an “atomic light” on cancer
Getting the right medicine to the right patient at the right time – it’s the goal of precision medicine, an approach that takes into account the fact that every patient is different. When it comes to cancer, precision medicine is particularly important. Why? Because cancer is incredibly complex and, in many ways, as unique as the individual who happens to possess the condition.
So how do we improve our odds of knowing whether a medicine may be right for a patient? One potential strategy may be to shine a light on cancer – with atomic energy.
See it, treat it
We’re excited here at Novartis about radioligand therapy – an approach for delivering radiation particles to cancers. It has two primary components. First, there’s a special molecule designed to seek out target proteins that some cancers express in high amounts. Attached to the molecule is a therapeutic radioisotope – an atom that emits a specific form of energy.
When given to a patient systemically, these molecules are designed to circulate throughout the body, attaching to cells that express the target protein, including cancer cells. If the molecules successfully converge onto a tumor, the combined radiation can potentially damage it, with a goal of limiting damage to healthy cells.
But that’s not the only reason we’re excited. Radioligand therapy is a technology platform – a foundational tool that can be tailored for different needs.
Atomic light bulb
Its core components, the special targeting molecule and the radioisotope, can be mixed and matched like toy building blocks. Instead of a therapeutic radioisotope, we can use an imaging radioisotope – one that acts like a light bulb to reveal cancer cells wherever they are in the body.
If a patient’s tumor shows positive uptake of the imaging radioisotope, this imaging approach, called radioligand imaging, can potentially help doctors visually determine which patients are most likely to benefit from radioligand treatment before they receive it.
At Novartis, we’ve already developed radioligand therapies for certain types of cancers. We’re working on exploring more special targeting molecules and different radioisotopes, which can be mixed and matched to hopefully bring this approach to more types of cancer and more patients. In this emerging area of medicine, possibilities for combinations with other methods of treating cancer also remain to be explored.
Next week, we’ll talk another exciting approach – one that’s driving another potential pillar for cancer care, next-gen CAR-T therapy.
Asstt Manager - Corporate Relations @ RKGIT Spl. B.Tech B.Pharm M.Pharm. D.Pharm
2moDear HR Team Novartis I have BPharm and MPharm 2024 batch to be placed. If you wish to hire freshers kindly share the JD tpo@rkgit.edu.in or call 9582024139. Regards Binoy Krishna
Truth & Vision
1yLike I-131 isotope
Healthcare | Clinical | Surgery | Researcher | MBA | Health Projects Management | Professor | Medical Ethics | Subject Matter Expert | DM2 | Regulatory Affairs | Academia | Biotechnology Immuno-oncology |Liver Transplant
1yOutstanding job!! Congratulations to Novartis!!
Life Cycle Manager at Novartis
1yBest wishes to all who are working on the project and aim for achieving succes……..
FP&A|ERP|Corporate|Management Reporting|Tax|Inter-company|Data Management| IFRS| Compliance|Change Transformation Consultant Partner|Associate CFO|No interest in Bitcoin/Crypto Trading.
1yInsightful! Thank you for sharing Novartis team. Personalized approach is the key factor. Everyone’s genomics 🧬 patterns are unique=naturally personalisation, hence a personalised treatment approach will certainly achieve a better outcome for patients. Best wishes.🙏🙏